Abstract
RAS mutations are among the most common genetic alterations found in cancerous tumors but rational criteria or strategies for targeting RAS-dependent tumors are only recently emerging. Clinical and laboratory data suggest that patient selection based on specific RAS mutations will be an essential component of these strategies. A thorough understanding of the biochemical and structural properties of mutant RAS proteins form the theoretical basis for these approaches. Direct inhibition of KRAS G12C by covalent inhibitors is a notable recent example of the RAS mutation-tailored approach that establishes a paradigm for other RAS mutation-centered strategies.
Original language | English (US) |
---|---|
Pages (from-to) | 263-271 |
Number of pages | 9 |
Journal | Future Oncology |
Volume | 13 |
Issue number | 3 |
DOIs | |
State | Published - Feb 2017 |
Keywords
- GTPase
- RAS
- cancer
- isoforms
ASJC Scopus subject areas
- Oncology
- Cancer Research